【摘要】 阿莫曲坦(almotriptan,LAS-31416)是第5个上市的曲坦类新药,是经结构改造开发的新型第二代选择性5-HT1b/1D受体激动剂,它克服了舒马曲坦的某些不良反应,具有很高的血管选择性,耐受性好,可以替代其他曲坦类药物治疗中度或严重的偏头痛,有较广阔的市场前景。对阿莫曲坦的药动学、临床疗效、不良反应、药物相互作用等进行了阐述。更多还原

【Abstract】 Almotriptan, as one of second-generation 5-HT18/1D receptor agonists, is the fifth new drug with triptan skeleton for the abortive treatment of migraine headaches on the marketing. Almotriptan works by stopping abnormal dilation of blood vessels in the head, fighting inflammation, and reducing pain transmissions along certain nerve pathways near the brain. Its side effect profile is similar to other triptans, except that it had significantly less chest pain associated with its use. Almotriptan is a good option for patients unable to tolerate other triptans because of chest pain. However, because of the potential of this class of compounds to cause coronary vasospasm, almotriptan should not be given to patients with documented ischemic or vasospastic coronary artery disease. This review provided up-to-date information on almotriptan including the pharmacokinetics, clinical therapeutics and safety, drug interactions and cost comparison.更多还原